Russian Heart Failure Journal 2008year Immunocorrecting properties of statins in the treatment of dilated cardiomyopathy


To access this material please log in or register

Register Authorize
2008/

Immunocorrecting properties of statins in the treatment of dilated cardiomyopathy

Belenkov Yu. N., Tatenkulova S. N., Mareev V. Yu., Masenko V. P., Balakhonova T. V., Tripoten M. I., Bosykh E. G., Kuznetsova T. V., Kechedzhieva N. P., Zykov K. A.

Keywords:

DOI:

Urgency. The use of statins in dilated cardiomyopathy (DCMP) was promising in some studies: clinical course of disease and heart contractility improved; levels of proinflammatory cytokines and mortality decreased. Aim. Studying mechanisms of immunotropic effects of statins in DCMP. Materials and methods. Major markers of immune activation were studied in 44 patients with DMP and CHF including 42 (95 %) men and 2 (5 %) women aged 22 to 61 years. LV systolic and diastolic function was evaluated. Levels of CRP, IgG, IgA, and IgM were measured using the nephelometric method. Serum levels of NT-proBNP, IL-6, sIL-2R, IL-8, IL – 18, IL-10 and IFN-γ were measured using the immune-enzyme assay. The 6‑min walking test was performed. For efficacy, tolerability and safety analyses, a single dose of atorvastatin 10 mg was used. Results. The use of statin improved the clinical course of disease; reduced CHF FC, and degree of cardiac decompensation. Improvements of endothelial function and parameters of heart diastolic function were not observ.
  1. Ahmad F, Seidman JG, Seidman CE. The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet. 2005; 6:185‑216.
  2. Kaski J. P, Elliott P; ESC Working Group.The classification concept of the ESC Working Group on myocardial and pericardial diseases for dilated cardiomyopathy. Herz. 2007; 32 (6):446‑451.
  3. Caforio AL, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail. 2002; 4 (4):411‑417.
  4. Caforio AL, Bonifacio E, Keeling PJ et al. [Idiopathic dilated cardiomyopathy: a persistent viral infection or an organ-specific autoimmune disease? The trial of 2 major pathogenetic hypotheses]. G Ital Cardiol. 1992; 22 (1):63–72.
  5. Maisch B, Richter A, Sandmöller A et al. BMBF-Heart Failure Network. Inflammatory dilated cardiomyopathy (DCMI). Herz. 2005; 30 (6):535‑544.
  6. Maisch B. [Classification of cardiomyopathies according to the WHO / ISFC Task Force--more questions than answers?]. Med Klin (Munich). 1998; 93 (4):199‑209.
  7. Burian J, Buser P, Eriksson U. Myocarditis: the immunologist’s view on pathogenesis and treatment. Swiss Med Wkly. 2005; 135 (25–26):359‑364.
  8. Maisch B, Hufnagel G, Kölsch S et al. Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins. Herz. 2004; 29 (6):624‑636.
  9. Maisch B, Herzum M, Hufnagel G et al. Immunosuppressive treatment for myocarditis and dilated cardiomyopathy. Eur Heart J. 1995; 16 (Suppl O):153‑161.
  10. Sola S, Mir MQ, Lerakis S et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006; 47 (2):332‑337.
  11. Dickinson MG, Ip JH, Olshansky B et al. SCD-HeFT Investigators. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights fr om the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2007; 153 (4):573‑578.
  12. Иванова О. В., Балахонова Т. В., Соболева Г. Н. и др. Состояние эндотелийзависимой вазодилатации плечевой артерии у больных гипертонической болезнью, оцениваемое с помощью ультразвука высокого разрешения. Кардиология. 1997; 37 (7):41–45.
  13. Fu M. Autoimmunity and idiopathic dilated cardiomyopathy: wh ere we stand? Autoimmunity. 2008; 41 (6):415‑418.
  14. Hufnagel G, Pankuweit S, Maisch B. [Therapy of dilated cardiomyopathies with and without inflammation]. Med Klin (Munich). 1998; 93 (4):240‑251.
  15. Pankuweit S, Hufnagel G, Eckhardt H et al. [Cardiotropic DNA viruses and bacteria in the pathogenesis of dilated cardiomyopathy with or without inflammation]. Med Klin (Munich). 1998; 93 (4):223‑228.
  16. Martin G, Duez H, Blanquart C et al. Statin – induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest. 2001; 107 (11):1423–1432.
  17. Delerive P, De Bosscher K, Besnard S et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999; 274 (45):32048–32054.
  18. Delerive P, Gervois P, Fruchart J, Staels B. Induction of IkBa expression as a mechanism contributing to the anti-inflammatory activities of peroxisome prolifeerator-activated receptor-α activators. J Biol Chem. 2000; 275 (47):36703–36707.
  19. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336 (15):1066–1071.
  20. Ortego M, Bustos C, Hernández-Presa MA et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999; 147 (2):253‑261.
  21. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as newly recognized type of immunomodulator. Nat Med. 2000; 6 (12):1399–1402.
  22. Domanski M, Coady S, Fleg J et al. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]). Am J Cardiol. 2007; 99 (10):1448–1450.
  23. Gissi-Hf Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008. [Epub ahead of print]
  24. Athyros VG, Kakafika AI, Tziomalos K et al. CORONA, statins, and heart failure: who lost the crown? Angiology. 2008; 59 (1):5–8.
  25. Tatli E, Kurum T. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Can J Cardiol. 2005; 21 (4):344‑348.
  26. Gundogdu F, Bozkurt E, Kiziltunc A et al. The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure. Echocardiography. 2007; 24 (2):113‑117.
  27. Wang F, Xu ZM, Wang L et al. [Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure]. Zhonghua Nei Ke Za Zhi. 2005; 44 (7):490‑494.
  28. Mayer B, Holmer SR, Hengstenberg C et al. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int J Cardiol. 2005; 103 (2):182‑186.
  29. Gonseth J, Guallar-Castillon P et all. The effectiveness of disease management programmes in reducing hospital re-admission in older patient with heart failure: a systematic review and meta-analysis of published reports. Eur Heart J. 2004; 25 (18):1570–1595.
  30. Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis. 2007; 50 (6):1009–1019.
  31. Hess G, Moecks J, Zdunek DN. Terminal-proBNP (NT-proBNP) as an indicator of cardiac dysfunction. A study in patients presenting with suspected cardiac disorders. Z Kardiol. 2005; 94 (4):247‑254.
  32. Karabulut A, Kaplan A, Aslan C et al. The association between NT-proBNP levels, functional capacity and stage in patients with heart failure. Acta Cardiol. 2005; 60 (6):631‑638.
  33. Birner CM, Ulucan C, Fredersdorf S et al Head-to-head comparison of BNP and IL-6 as markers of clinical and experimental heart failure: Superiority of BNP. Cytokine. 2007; 40 (2):89–97.
  34. Sola S, Mir MQ, Lerakis S et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006; 47 (2):332‑337.
  35. Okura H, Asawa K, Kubo T et al. Impact of statin therapy on systemic inflammation, left ventricular systolic and diastolic function and prognosis in low risk ischemic heart disease patients without history of congestive heart failure. Intern Med. 2007; 46 (17):1337–1343.
  36. Huan Loh P, Windram JD, Tin L et al. The effects of initiation or continuation of statin therapy on cholesterol level and all-cause mortality after the diagnosis of left ventricular systolic dysfunction. Am Heart J. 2007; 153 (4):537‑544.
  37. Tousoulis D, Antoniades C, Bosinakou E et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis. 2005; 178 (2):359‑363.
  38. Hsu HY, Wang PY, Chen YT et al. Changes in flow-mediated dilatation, cytokines and carotid arterial stenosis during aggressive atorvastatin treatment in normocholesterolemic patients. J Chin Med Assoc. 2005; 68 (2):53–58.
  39. Sánchez Muñoz-Torrero JF, Crespo Rincón L, Fernández Pereira L et al. [Effects of atorvastatin in N-terminal pro-brain natriuretic peptide plasma levels in hypercholesterolemic patients with or without hypertension]. Med Clin (Barc). 2006; 127 (14):521‑525.
  40. Sola S, Mir MQ, Lerakis S et al Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006; 47 (2):332‑337.
  41. Stefanadi E, Tousoulis D, Antoniades C et al. Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation. Int J Cardiol. 2008 Jan 8. [Epub ahead of print]
  42. Suzuki H, Sato R, Sato T et al. Time-course of changes in the levels of interleukin 6 in acutely decompensated heart failure. Int J Cardiol. 2005; 100 (3):415‑420.
  43. Stumpf C, Seybold K, Petzi S et al. Interleukin-10 improves left ventricular function in rats with heart failure subsequent to myocardial infarction. Eur J Heart Fail. 2008; 10 (8):733‑739.
  44. Stumpf C, Petzi S, Seybold K et al. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction. Clin Sci (Lond). 2008 May 6. [Epub ahead of print]
  45. Stumpf C, Seybold K, Petzi S et al. Interleukin-10 improves left ventricular function in rats with heart failure subsequent to myocardial infarction. Eur J Heart Fail. 2008; 10 (8):733‑739.
  46. Heeschen C, Dimmeler S, Hamm CW et al. CAPTURE Study Investigators. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 2003; 107 (16):2109–2114.
  47. Wang M, Markel TA, Meldrum DR. Interleukin 18 in the heart. Shock. 2008; 30 (1):3–10.
  48. Jawień J. New insights into immunological aspects of atherosclerosis. Pol Arch Med Wewn. 2008; 118 (3):127‑131.
  49. Eslick GD, Thampan BV, Nalos M et al. Circulating interleukin-18 concentrations and a loss-of-function P2X7 polymorphism in heart failure. Int J Cardiol 2008. [Epub ahead of print]
  50. Souza KL, Gurgul-Convey E, Elsner M, Lenzen S. Interaction between pro-inflammatory and anti-inflammatory cytokines in insulin-producing cells. J Endocrinol. 2008; 197 (1):139‑150.
  51. Sharma JN, Al-Omran A, Parvathy SS. Role of nitric oxide in inflammatory diseases. Inflammopharmacology. 2007; 15 (6):252‑259.

To access this material please log in or register

Register Authorize
Ru En